are winners!

Top News

Public disclosure of inside information according to article 17 MAR Martinsried/Munich (28.01.2020/18:25) - 28 January 2020. The Executive Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard) today decided to adjust its previous 2019 full-year guidance on EBITDA loss. In relation with the sale of Veregen®, which took place in April 2019, the inventories of the active pharmaceutical ingredient were revalued by EUR 4.7 million in the "Inventories". This cash neutral loss which was previously taken into account in 2019 will now be accounted for retroactively in the fiscal year 2018 after receiving the assessment result ... [ more ]